Indwelling urinary catheter assembled with lidocaine‐loaded polymeric strand for local sustained alleviation of bladder discomfort

Kim, Cho Rim; Jang, Eun Bi; Yoon, Young Eun; Huh, Beom Kang; Kim, Se Na; Kim, Min Ji; Moon, Hong Sang; Choy, Young Bin

doi:10.1002/btm2.10218

Cited by 8 publications

(10 citation statements)

References 73 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Polymer gels loaded with drugs have been shown to achieve prolonged, steady drug release 41–44 . In the mucoadhesive property experiment, both the chitosan and CT were retained on the mucus layer in the first 2 h (Figure 5).…”

Section: Discussionmentioning

confidence: 99%

“…Polymer gels loaded with drugs have been shown to achieve prolonged, steady drug release. [41][42][43][44] In the mucoadhesive property experiment, both the chitosan and CT were retained on the mucus layer in the first 2 h (Figure 5). When the medium was continuously perfused to mimic the vaginal environment, CT showed enhanced mucoadhesive properties compared to chitosan because CT could form covalent disulfide bonds with the mucus layer of the mucosal tissue to extend the retention time, which would enable the slow release of DEHP to avoid the self-cleaning mechanism of the vagina.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Development of di(2‐ethylhexyl) phthalate‐containing thioglycolic acid immobilized chitosan mucoadhesive gel as an alternative hormone therapy for menopausal syndrome

Yang

Lin

Liang

et al. 2021

Bioengineering & Transla Med

View full text Add to dashboard Cite

Menopausal syndrome includes the symptoms that most women experience owing to hormone changes after menopause. Although hormone replacement therapy is a common treatment for menopausal syndrome, there are still many side effects and challenges hindering research. In this study, thioglycolic acid (TGA)‐immobilized chitosan mucoadhesive gel was synthesized by a new method of low concentration of 1,4‐butanediol diglycidyl ether (BDDE) would encapsulate di(2‐ethylhexyl) phthalate (DEHP) as an alternative hormone replacement therapy for menopausal syndrome. The efficacies of the DEHP‐containing TGA‐chitosan gel (CT‐D) were confirmed and evaluated by materials characterization and in vitro study. Results showed that CT‐D was not cytotoxic and had better mucoadhesive ability than chitosan. The animal model was constructed 1 month after bilateral ovariectomy in SD rats. CT‐D was administered intravaginally every 3 days. Bodyweight, wet weight of the uterus and vagina, vaginal smears, histology, blood element analysis, and serological analysis was used to assess the ability of the material to relieve menopausal syndrome. The results indicated that the combination of the sustained release of DEHP and mucoadhesive TGA‐immobilized chitosan allows the developed CT‐D to relieve the menopausal syndrome through low concentrations of DEHP, which falls in the safety level of the tolerable daily intake of DEHP.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Development of di(2‐ethylhexyl) phthalate‐containing thioglycolic acid immobilized chitosan mucoadhesive gel as an alternative hormone therapy for menopausal syndrome

Yang

Lin

Liang

et al. 2021

Bioengineering & Transla Med

View full text Add to dashboard Cite

show abstract

“…For removal, the balloon is deflated, and the catheter is simply pulled out. Prolonged release of an anesthetic for reducing the pain induced by IUC has been recently proposed by Kim and co-authors, who designed a drug-loaded polymer strand releasing lidocaine up to 7 days ( Kim et al, 2021 ). The thin poly(lactic- co -glycolic acid) (PLGA) strand was wrapped around the external tube of the urinary catheter and released the drug from the surface thus alleviating the discomfort associated with the presence of the device ( Fig.…”

Section: Administration Of Drugs Into the Bladder And Relevant Open Issuesmentioning

confidence: 99%

“…2 Schematic of the fabrication procedure of strand-wrapped indwelling urethral catheters for lidocaine release. Reprinted with permission from ( Kim et al, 2021 ). …”

Section: Administration Of Drugs Into the Bladder And Relevant Open Issuesmentioning

confidence: 99%

Intravesical drug delivery approaches for improved therapy of urinary bladder diseases

Palugan

Cerea

Cirilli

et al. 2021

International Journal of Pharmaceutics: X

View full text Add to dashboard Cite

Diseases of the urinary bladder have high incidence rates and burden healthcare costs. Their pharmacological treatment involves systemic and local drug administration. The latter is generally accomplished through instillation of liquid formulations and requires repeated or long-term catheterization that is associated with discomfort, inflammation and bacterial infections. Consequently, compliance issues and dropouts are frequently reported. Moreover, instilled drugs are progressively diluted as the urine volume increases and rapidly excreted. When penetration of drugs into the bladder wall is needed, the poor permeability of the urothelium has also to be accounted for. Therefore, much research effort is spent to overcome these hurdles, thereby improving the efficacy of available therapies. Particularly, indwelling delivery systems suited for i) insertion into the bladder through the urethra, ii) intra-organ retention and prolonged release for the desired time lapse, iii) final elimination, either spontaneous or by manual removal, have been proposed to reduce the number of catheterization procedures and reach higher drug levels at the target site. Vesical retention of such devices is allowed by the relevant expansion that can either be triggered from the outside or achieved exploiting elastic and purposely 4D printed shape memory materials. In this article, the main rationales and strategies for improved intravesical delivery are reviewed.

show abstract

“…In this regard, localized administration is an appropriate alternative treatment strategy, because it can maintain the original molecular structure of medicines, permitting the direct and precise use of target drugs as well as expanding the range available [ [4] , [5] , [6] , [7] ]. In the lower urinary tract, localized drug delivery can be achieved by irrigation of the medicine into the bladder via a urethral catheter [ [8] , [9] , [10] ]. However, this method is not suitable for the treatment of upper urinary tract diseases.…”

Section: Introductionmentioning

confidence: 99%

Ultrathin, elastic, and self-adhesive nanofiber bio-tape: An intraoperative drug-loading module for ureteral stents with localized and controlled drug delivery properties for customized therapy

Gao

Zhao

et al. 2022

Bioactive Materials

View full text Add to dashboard Cite

Indwelling urinary catheter assembled with lidocaine‐loaded polymeric strand for local sustained alleviation of bladder discomfort

Abstract: This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the Version of Record. Please cite this article as

Cited by 8 publications

References 73 publications

Development of di(2‐ethylhexyl) phthalate‐containing thioglycolic acid immobilized chitosan mucoadhesive gel as an alternative hormone therapy for menopausal syndrome

Development of di(2‐ethylhexyl) phthalate‐containing thioglycolic acid immobilized chitosan mucoadhesive gel as an alternative hormone therapy for menopausal syndrome

Intravesical drug delivery approaches for improved therapy of urinary bladder diseases

Ultrathin, elastic, and self-adhesive nanofiber bio-tape: An intraoperative drug-loading module for ureteral stents with localized and controlled drug delivery properties for customized therapy

Contact Info

Product

Resources

About